NCT06387056View on ClinicalTrials.gov

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2029

Conditions
Locally Advanced Prostate CancerOligometastatic Prostate Cancer
Interventions
DRUG

Rezvilutamide

240mg by mouth once a day for 24 weeks.

DRUG

Goserelin Microspheres for Injection

3.6mg by intramuscular injection once 4 weeks for 24 weeks.

DRUG

Docetaxel

70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

DRUG

Pamiparib

60mg by mouth twice a day for 20 weeks.

DRUG

Cisplatin

70mg/m2 by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

DRUG

Tislelizumab

200 mg by infusion every 3 weeks for 6 cycles (each cycle has 3 weeks).

Trial Locations (1)

361000

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER